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ABSTRACT
Cannabinoid (CB) and opioid systems are both involved in analgesia, food intake, mood and behavior. Due
to the co-localization of m-opioid (MOR) and CB1 receptors in various regions of the central nervous system
(CNS) and their ability to form heterodimers, bivalent ligands targeting to both these systems may be
good candidates to investigate the existence of possible cross-talking or synergistic effects, also at sub-
effective doses. In this work, we selected from a small series of new Rimonabant analogs one CB1R reverse
agonist to be conjugated to the opioid fragment Tyr-D-Ala-Gly-Phe-NH2. The bivalent compound (9) has
been used for in vitro binding assays, for in vivo antinociception models and in vitro hypothalamic perfu-
sion test, to evaluate the neurotransmitters release.
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Introduction
Cannabinoid and opioid receptors are expressed mostly in the
same CNS areas, and both are involved in the control of analgesia,
food intake, mood and behavior. In the dorsal horn of the spinal
cord, the m-opioid receptor MOR and CB1R are co-localized at the
same neurons, also at the supra-spinal level, such as the periaque-
ductal gray (PAG), the raphe nuclei and the central-medial thal-
amic nuclei1.
According to the several cell line studies where the MOR and
CBR1 are endogenously co-expressed, they share cAMP signaling
pathways, even though they may use different sets of G-proteins2.
Studies on opioid and CB1R knock-out mice, demonstrated that
their density and activity strongly depend on each other3,4. Also,
preclinical and clinical studies stated that the interaction between
the opioid and cannabinoid systems can lead to promising thera-
peutic applications in pain control and in alimentary disorders
management5–8. Thus, bivalent ligands binding to CB1R and MOR
simultaneously may result in new potent analgesic agents.
Recently, Le Naour et al.6 proposed a bivalent approach to target
both MOR and CB1R, connecting a selective MOR agonist to a
CB1R selective inverse agonist, via a spacer group of varied length.
One of the synthesized compounds showed an extremely
potent activity in in vivo antinociceptive tests and was devoid of
tolerance. Additive or synergic interactions between opioid and
cannabinoid systems in producing analgesia have been previously
described and reviewed in detail9,10. Morphine-induced
antinociception is completely reversed by the CB1R antagonist
AM25111, and tetrahydrocannabinol (THC)-induced antinociception
is blocked by naloxone12.
The cross-tolerance between THC and morphine and the possi-
bility that these receptors interact pharmacologically were demon-
strated by naloxone or CB1R antagonist. Synergism between
cannabinoids and opioids at sub-effective doses has also been
reported13,14. Additionally, co-administration of morphine with a
CB1R antagonist inhibited the development of both acute and
chronic tolerance to morphine15.
Other evidence for interaction was obtained from self-adminis-
tration studies showing that both receptors are involved in reward
processes. In this regard, both CB1R antagonist (SR 141716)16, and
opioid antagonist naloxone decreased self-administration of mor-
phine or D9-THC17. In mice lacking m (MOR) and d (DOR) opioid
receptors, the cannabinoid withdrawal syndrome is reduced18.
According to our research line based on the design of multitar-
get compounds19,20, the present study represents a starting point
to develop bivalent ligands as pharmacologic tools to investigate
the MOR–CB1R mutual interactions. The bivalent ligand designed
for this purpose consists of a selective m-receptor peptide agonist
connected to a CB1R selective inverse agonist fused together21.
The novel compound was extensively tested for in vitro bind-
ing, GTP stimulation, neurotransmitters release and antinociceptive
in vivo activity. The design rationale for targeting MOR and CB1R
simultaneously is based on previous studies with bivalent ligands6.
The MOR agonist pharmacophore derived from the opioid peptide
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biphalin, was previously employed in the design of several
bivalent compounds, due to its property to well tolerate the con-
nection at the C-terminus with another pharmacophore22,23,19.
Since other authors show that a CB1R inverse agonist is cap-
able of eliminating morphine tolerance and dependence24,25, we
selected compound 5 (Scheme 1) with CB1R inverse agonist activ-
ity as CB1R pharmacophore (Figure 1), in analogy with the work
by Le Naour et al.6
Thus, the bivalent ligand 9 was synthesized following the
“fused-bivalent approach”21, with the expectation that the result-
ing product would be capable to interact at CB1R, MOR and
CB1R–MOR heterodimer form. The bivalent compound was pre-
pared by coupling each Boc-protected amino acid of the opioid
peptide sequence to the secondary amine of 4-aminopiperidine
group present in the structure of Rimonabant analog 5.
The opioid fragment Tyr-D-Ala-Gly-Phe-NH2 (10) was used as
reference compound for opioid activity on MOR and DOR19.
Results and discussion
A series of novel 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxa-
mides Rimonabant analogs were tested for the stimulation of G
protein to evaluate their inverse agonist activity at CB1R to
develop a bivalent compound (Scheme 1).
Compounds 1 and 2 have been previously synthesized and
characterized by Silvestri et al.26 for the development of potent
CBR1 inverse agonists. The molecules were designed by pursuing
a bioisosteric approach on Rimonabant, from which 5 resulted to
be one of the most interesting candidate with the advantage to
be easily derivatisable by coupling with an opioid peptide on the
piperidine secondary nitrogen in place of the tert-butoxycarbonyl
(Boc) group. Indeed N-Boc derivative 3 resulted to be active,
showing that the substitution of a bulky moiety at the secondary
nitrogen of the 4-aminopiperidine terminus was possible without
any loss of activity. Firstly, we investigated the cannabinoid recep-
tor (CBR) binding affinity of the Rimonabant analogs compared
with Rimonabant in competition binding assays using the nonse-
lective cannabinoid receptor radioligand [3H]WIN55 212
(CB1R<CB2R) (Figure 2). In this test, the Rimonabant analogs 1–4
exhibited nanomolar Ki values: compounds 1 (Ki ¼125.9 nM) and
3 (Ki ¼192.9 nM) were the most potent derivatives as compared
with Rimonabant (Ki ¼25 nM) (Table S1, see SI)27,28.
In the following step, we investigated the effect of Rimonabant
and its analogs on G-protein activity. In these experiments, we
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Scheme 1. Synthesized Rimonabant analogs.
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Figure 1. Structure of bivalent compounds previously designed by Le Naour et al.6
Figure 2. The binding affinity of Rimonabant and its analogs on CBR (A) and the MOR (B), DOR (C), KOR (D) and CBR binding affinity of 5, 9 and 10 (Tyr-D-Ala-Gly-Phe-
NH2) (E) in competition binding experiments. Figures represent the specific binding of [
3H]WIN55 212–2, [3H]DAMGO, [3H]IleDelt II and [3H]HS665 in percentage in the
presence of increasing concentrations (1011–105 M) of the indicated unlabeled ligands performed in rat (A, B and E) or in guinea pig (D) whole brain membrane
homogenates. “Total” on the x-axis indicates the total specific binding of radioligand, which is measured in the absence of the unlabeled compounds. The level of total
specific binding was defined as 100% and is presented with a dotted line. Points represent means ± SEM for at least three experiments performed in duplicates.
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determined their agonist, antagonist or inverse agonist nature.
The experiments were performed by [35S]GTPcS binding assays to
control the GDP to GTP exchange of the a-subunit of Gi-protein.
The analogs 1, 2, 3 and 4 decreased [35S]GTPcS specific binding
(thus G-protein activity) compared with basal activity by more
than 80% (Emax¼ 17.5). Compounds 1–4 showed strong reduction
of G-protein activity comparable to Rimonabant29–31 and therefore
displayed inverse agonist effects (Table 1). We examined the opi-
oid receptor binding affinity of 5 in competition binding experi-
ments, using opioid receptor selective radioligands. As expected,
5 did not bind to MOR and DOR and the affinity for the KOR was
negligible (Table 1S, Figure 2(B–D))31–37.
Opioid fragment 10 displayed a high affinity for MOR and DOR
(MOR>DOR), while the compound had modest affinity for KOR,
even at high nanomolar concentration (Table S1). As expected, the
opioid peptide fragment did not show any affinity for CBR1 (Table
1S, Figure 2(E)); it increased G-protein activity with a maximum
efficacy (Emax) of nearly 70% above basal activity with EC50 of 81.
3 nM, thus we can assert that this compound behaved as an
agonist.
In the second part of our work, the designed bivalent com-
pound 9 was synthesized (Scheme 2) and fully characterized
(see SI). Peptide 10 has been prepared following the standard syn-
thetic procedure for coupling reactions19.
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Table 1. The maximal G-protein efficacy (Emax) and ligand potency (logEC50) of
the Rimonabant and its analogs 1, 2, 3, 4, 5, bivalent compound 9 and opioid
peptide 10 in [35S]GTPcS binding assays on rat brain membrane homogenates.
The values were calculated according to dose–response curves in Figure S1 (see
SI) as described in the “Data analysis” section.
Emax ± S.E.M. (%) LogEC50 ± S.E.M. (EC50)
Rimonabant 17.5 ± 5.72 5.65 ± 0.12 (2.2lM)
1 26 ± 5.27 5.78 ± 0.11 (1.62 lM)
2 22.95 ± 4.3 5.81 ± 0.09 (1.54 lM)
3 12.78 ± 8.48 5.57 ± 0.15 (2.69 lM)
4 55.95 ± 8.44 5.72 ± 0.3 (1.87 lM)
5 99.2 ± 46.1 ambiguous
Bivalent compound (9) 36.62 ± 10.35 5.44 ± 0.21 (3.6lM)
Tyr-D-Ala-Gly-Phe-NH2 (10) 161.5 ± 4.08 7.09 ± 0.22 (81.3 nM)
Since the compound did not alter significantly the total specific binding of the
radioligand, thus logEC50 values cannot be interpreted.
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Compound 9 behaved as inverse agonist as it decreased
[35S]GTPcS specific binding, thus reducing G-protein activity com-
pared with the basal level (Table 1). Attaching the opioid fragment
to Rimonabant analog 5 to give the bivalent compound 9 resulted
in a rather selective DOR ligand with an unexpected improvement
of affinity for KOR, and a loss in affinity for MOR and DOR, as com-
pared with the opioid fragment alone (Table S1, Figure 2(B–D)).
According to the affinities displayed by the opioid peptide 10 and
5, the bivalent compound 9 showed modest affinity towards CB1R
(Table S1, Figure 2(E)).
The results obtained in the hot plate and tail flick tests after
i.c.v. injection in mice, are reported in Figure 3. In these experi-
ments, compound 9 was administered i.c.v. at doses of 1, 5 and
10mg/mouse. Neither in the hot plate nor in the tail flick test
treatments modified the behavioral response to thermal nocicep-
tive stimuli. In the hot plate test, two-way ANOVA revealed no dif-
ference in treatments [F3,120¼2.65, p¼ 0.522] and in time
[F4,120¼2.30, p¼ 0.0629] paradigms. Similar absence of effect was
observed in the tail flick test, since treatment [F3,120¼2.6,
p¼ 0.0551] did not affect the latency of the nociceptive response
all over the time [F4,120¼1.32, p¼ 0.2649].
To further explore the pharmacologic profile of the bivalent lig-
and, hypothalamic perfusion test was performed with the aim to
compare the release of hypothalamic neurotransmitters, after
administration of the two separate pharmacophores and com-
pound 9 in the preparation of synaptosomes. In this experiment,
the three combinations produced different effects, showing a pos-
sible influence of the contemporary stimulation of CBRs and opi-
oid systems on neurotransmitters release. As regards to 10, we
found a significant stimulatory effect on norepinephrine (NE) and
an inhibitory effect on serotonin (5-HT) and dopamine (DA)
release, from hypothalamic synaptosomes (Figures 4 and 5).
Administration of compound 5 decreased only the DA release,
whereas the treatment with 9 resulted in the reduction of the NE
release’s stimulation and DA inhibition (in less extent), with no sig-
nificant effects on the 5-HT release. This is consistent with the
inverse agonist activity on the G-protein system of compound 9.
The significant stimulatory effect on NE release could indicate a
possible involvement in the regulation of energy balance. By con-
trast, the reduced inhibitory effect on hypothalamic DA release,
Figure 3. Hot-plate and Tail flick test. In these experiments, compound 9 (C9) was administered i.c.v. at doses of 1, 5 and 10lg/mouse. V is for vehicle. N¼ 10.
Ve
hic
le  
Co
m
po
un
d  1
0
Co
m
po
un
d  
9
Co
m
po
un
d  
5
0
50
100
150
200
250
***
**
%
 N
E 
re
le
as
e
Ve
hic
le 
 
Co
m
po
un
d 1
0
Co
mp
ou
nd
 9
Co
mp
ou
nd
 5
0
50
100
150
***
**
***
%
   
D
A
   
re
le
as
e
Figure 4. Effect of opioid peptide 10, bivalent compound 9 and 5 on NE and DA release from hypothalamic synaptosomes, in vitro. ANOVA p< 0.0001, p< 0.001,p< 0.01 vs. vehicle.
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Figure 5. Effect of opioid peptide 10, bivalent compound 9 and 5 on 5-HT release
from hypothalamic synaptosomes, in vitro. ANOVA p< 0.05, p< 0.05 vs. vehicle.
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compared with both parent molecules, is coherent with a minor
potential of behavioral adverse effects in vivo38,39.
The modulatory effects on hypothalamic biogenic amines sug-
gest a possible involvement of both 10 and 5 in the intercon-
nected neuronal pathways for the energy balance control. 5-HT
release plays an anorectic role in the hypothalamus40; DA injection
in the perifornical hypothalamus inhibited food intake41, while DA
administration in the lateral hypothalamus stimulated feeding42.
NE could also exert both anorexigenic and orexigenic effects,
related to the activation of a1- and a2-adrenoceptors, respect-
ively43. In addition, NE binding to hypothalamic a2-adrenoceptors
could increase energy expenditure, through the stimulated sympa-
thetic activity44. Previously, we observed that endomorphin-2 (EM-
2), a selective MOR agonist, was able to stimulate food intake45.
The orexigenic effect was, albeit partially, related to the stimulated
hypothalamic DA and NE activity which is also consistent with the
increased oxygen consumption induced by EM-2 administration to
mice46.
The Absorption, Distribution, Metabolism, Excretion and
Toxicity (ADMET) properties of compounds 5, 9 and 10 were
assessed by means of web servers and specialized programs.
Several tools are available to profile compounds ADMET properties
using in silico calculations. In Tables 2S–4S are reported the
admetSAR47, Molinspiration and cbligand.org ADMET calculated
properties. In general, compounds 5, 9 and 10 are not substrate
for cytochromes and present low toxicity profiles (Table 2).
Regarding adsorption, derivative 9 violates three Lipinski’s rules
(high MW, number of HB donators and acceptors) that could pre-
vent its oral bioavailability. AdmetSAR BBB and CACO predicted
permeability indicate compound 5 as likely permeable, while com-
pounds 9 and 10 are predicted at low probability to permeate
BBB and CACO cells. These values are somehow in agreement
with those reported in Table 4S where eight QSAR models indicate
5 as fully able to penetrate BBB, while 9 and 10 are predicted on
the edge among positive and negative BBB penetrating molecules,
as evinced from plots and threshold values reported in Table 5S.
To further inspect on possible BBB permeability, new models
were herein developed by means of the python programming lan-
guage, open-source cheminformatics library rdkit (www.rdkit.org),
mathematical and scientific libraries numpy and scipy, machine-
learning library scikit-learn48. Application of the two new models
confirmed that compound 5 is able to penetrate BBB, while com-
pounds 9 and 10, although predicted not able to penetrate BBB,
show some probability to cross the BBB. The graphical analyses of
similarity maps (Figure 2S) indicate the molecular portions likely
responsible for the positive/negative BBB penetration49.
According to our experiments, we can conclude that the recep-
tor binding profile and biological activity of the bivalent com-
pound 9 significantly changed compared with the individual
components. The bivalent compound 9 showed higher selectivity
for MOR than the enkephalin-like opioid peptide fragment 10.
More interestingly, it showed an improved KOR affinity compared
with 5 and 10. The stimulation of the G-protein system could be
explained by the inverse agonist effect of the bivalent compound.
The lack of antinociceptive effect deals with the biological profile
of an inverse agonist triggering the G-protein cascade. Also the
ADMET properties of 9 are critical and establish benchmarks for
further development of this class of bivalent compounds. Further
studies on an alternative design of novel bivalent compounds
based on an opioid peptide and a Rimonabant analog are cur-
rently undergoing in our laboratory.
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